Trials / Completed
CompletedNCT02996435
Smartphones to Improve Rivaroxaban ADHEREnce in Atrial Fibrillation
smartADHERE - Smartphones to Improve Rivaroxaban ADHEREnce in Atrial Fibrillation
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 139 (actual)
- Sponsor
- Janssen Scientific Affairs, LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to evaluate the effectiveness of an intervention with a mobile adherence platform, compared to physician- or nurse-guided standard of care, to improve medication adherence to rivaroxaban in participants who have recently initiated treatment with rivaroxaban for stroke prevention in atrial fibrillation based on an assessment of the proportion of days covered (PDC) of rivaroxaban treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | Mobile Application Intervention | Mobile phone application that sends reminders and allows participants to self-manage their medication adherence. Monitoring of participant adherence from this tool will be performed by the central coordinating center, which will send notifications or contact the participant based on the adherence history in accordance with the study protocol. |
| OTHER | No Intervention | Participants will receive physician- or nurse-guided standard of care. |
Timeline
- Start date
- 2016-12-21
- Primary completion
- 2018-03-22
- Completion
- 2018-03-22
- First posted
- 2016-12-19
- Last updated
- 2018-10-26
Locations
25 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02996435. Inclusion in this directory is not an endorsement.